Dosage equivalents of AT1-receptor antagonists available in Germany;Äquivalenzdosen der in Deutschland verfügbaren AT 1-Rezeptor-Antagonisten

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 44, 2003, Pages 2315-2318

  Dominiak, P ^a   Hauser W ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL; EPROSARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN; ACRYLIC ACID DERIVATIVE; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; BIPHENYL DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; IMIDAZOLE DERIVATIVE; PLACEBO; TETRAZOLE DERIVATIVE; THIOPHENE DERIVATIVE; VALINE;

BIOEQUIVALENCE; DRUG METABOLISM; DRUG STRUCTURE; GERMANY; PHARMACODYNAMICS; REVIEW; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ANTAGONISM; HUMAN; HYPERTENSION; PHARMACOKINETICS; TIME;

ACRYLATES; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BIPHENYL COMPOUNDS; CLINICAL TRIALS; GERMANY; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; PLACEBOS; RECEPTORS, ANGIOTENSIN; TETRAZOLES; THERAPEUTIC EQUIVALENCY; THIOPHENES; TIME FACTORS; VALINE;

EID: 0242659265     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-43181     Document Type: Review

References (18)

1. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7: 53-59
2. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H The LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003
3. Dominiak P, Heusch G. AT1-Rezeptor-Blockade. 1. Auflage, Steinkopff-Verlag Darmstadt, 1999
4. Dominiak P, Unger T. Angiotensin II AT1-Rezeptorantagonisten. 2. Auflage, Steinkopff-Verlag Darmstadt, 1999
5. Elliott WJ, Calhoun DA, DeLucca PT, Gazdick LP, Kerns DE, Zeldin RK. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther 2001; 23: 1166-1179
6. Fricke U, Klaus W. Neue Arzneimittel (Hrsg.) Fakten und Bewertungen von 1997 bis 2000 zugelassenen Arzneimittel. Wissenschaftliche Verlagsgesellschaft, 2002
7. Gradman AH, Lewin A, Bowling BT, Tonkon M, Deedwania PC, Kezer AE, Hardison JD, Cushing DJ, Michelson EL. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group. Heart Dis 1999; 1: 52-57
8. Hedner T, Himmelmann A The Eprosartan Multinational Study Group. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. J Hypertens 1999; 17: 129-136
9. Hedner T, Oparil S, Rasmussen K, Rapelli A, Gatlin M, Kobi P, Sullivan J, Oddou-Stock P. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999; 12: 414-417
10. Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E Irbesartan/ Losartan Study Investigators. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Am J Hypertens 1998; 11: 445-453
11. Lacourciere Y, Asmar R Candesartan/Losartan study investigators. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Am J Hypertens 1999; 12: 1181-1187
12. Littlejohn T, Mroczek W, Marbury T, Van der Maelen CP, Dubiel RF. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000; 16: 1123-1132
13. Mallion J, Siche J, Lacourciere Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13: 657-664
14. Mancia G, Korlipara K, Van Rossum P, Villa G, Silvert B. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7: 135-142
15. Monterroso VH, Rodriguez Chavez V, Carbajal ET, Vogel DR, Aroca Martinez GJ, Garcia LH, Cuevas JH, Lara Teran J, Hitzenberger G, Leao Neves P, Middlemost SJ, Dumortier T, Bunt AM, Smith RD Losartan Trial Investigators. Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Adv Ther 2000; 17: 117-131
16. Oparil S, Guthrie R, Lewin AJ, Marbury T, Reilly K, Triscari J, Witcher JA Irbesartan/Losartan Study Investigators. An elective-titration study of the comparative effectiveness of two angiotensin Il-receptor blockers, irbesartan and losartan. Clin Ther 1998; 20: 398-409
17. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001; 3: 283-291
18. Vidt DG, White WB, Ridley E, Rahman M, Harris S, Vendetti J, Michelson EL, Wang R; CLAIM Study Investigators. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Hum Hypertens 2001; 15: 475-480